Carmen Bozic, Vertex CMO
FDA expands approval for Vertex's CF drug Orkambi to infants under two years of age
The FDA on Friday expanded its approval of Vertex’s blockbuster cystic fibrosis pill Orkambi to include children between 12 and 24 months.
Orkambi first won …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
